Abstract 1166P
Background
The typical chemotherapy choice for patients with advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors (PNET) is on the combination of Capecitabine and Temozolomide (CAPTEM), based on the ECOG-ACRIN E2211 study. The standard CAPTEM includes capecitabine on days 1–14 and temozolomide on days 10-14, given in 28-day cycles. There is limited data on the efficacy of a CAPTEM regimen given in 21-day cycles for patients with PNET.
Methods
A retrospective analysis of patients with metastatic PNET treated with a 21-day CAPTEM regimen at a Tertiary Cancer Center. This modified CAPTEM protocol involved administering Capecitabine 1000 mg/m2/BID on days 1–14 and Temozolomide 150 mg/m2 on days 1–5 every 21 days. Patient and tumor characteristics, previous interventions, and outcomes were gathered from the medical records.
Results
The study included 22 patients, with a median age at diagnosis of 65.0 years (interquartile range [IQR] 46.8, 69.8). The tumors’ primary sites were in the pancreas (n=16), stomach (n=3), lung (n=1), and unknown (n=2). Seven patients (31.8%) received peptide-receptor radionuclide therapy (PRRT) before CAPTEM initiation, three (13.6%) received chemotherapy, and four (18.2%) received everolimus or sunitinib. The disease control rate was 57.1% with an objective response rate of 33.3%. Treatment-related adverse events were reported with grade G1/G2 in 12 patients (75.0%) and G3 in 4 (25.0%). In a multivariate logistic regression analysis, adjuster for age, sex, primary tumor site, grade and previous PRRT treatment, male sex was associated with a trend towards lower risk for disease progression (odds ratio [OR]=0.1, p=0.1) and previous PRRT treatment - with a higher risk (OR=16.2, p=0.08).
Conclusions
Our retrospective data support the effectiveness and tolerability of a modified CAPTEM protocol given in 21-day cycles in patients with advanced well-differentiated PNET.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1417P - Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons
Presenter: Elizabeth Smyth
Session: Poster session 17
1418P - Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial
Presenter: Manavi Sachdeva
Session: Poster session 17
1419P - Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102)
Presenter: Lin Shen
Session: Poster session 17
1420P - Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Presenter: Seiya Sato
Session: Poster session 17
1421P - Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
Presenter: Joshua Tobias
Session: Poster session 17
1422P - First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
Presenter: Fernando Rivera Herrero
Session: Poster session 17
1423P - Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
Presenter: Elena Elimova
Session: Poster session 17
1424P - Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 17
1426P - BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Liu Chang
Session: Poster session 17